Violich Capital Management Inc. Sells 10,200 Shares of Pfizer Inc. $PFE

Violich Capital Management Inc. cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 24.7% during the second quarter, Holdings Channel.com reports. The fund owned 31,037 shares of the biopharmaceutical company’s stock after selling 10,200 shares during the period. Violich Capital Management Inc.’s holdings in Pfizer were worth $752,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer in the first quarter worth about $27,000. North Capital Inc. bought a new stake in shares of Pfizer in the first quarter worth about $28,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer in the first quarter worth about $28,000. Harbor Asset Planning Inc. bought a new stake in shares of Pfizer in the second quarter worth about $29,000. Finally, Horizon Financial Services LLC purchased a new position in Pfizer in the first quarter worth about $35,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $24.52 on Friday. The firm has a 50 day moving average of $24.89 and a 200 day moving average of $24.11. The company has a market capitalization of $139.38 billion, a price-to-earnings ratio of 13.04, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.36.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Wall Street Analyst Weigh In

Several research firms recently commented on PFE. Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. UBS Group reiterated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Finally, Bank of America lifted their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $28.13.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.